第21版，《世界卫生组织卫生紧急情况方案流行病学公报》，世界卫生组织东南亚区域办事处，2025年10月22日。报告期：2025年9月6日至10月19日

EpidemiologicalBulletin WHO Health Emergencies ProgrammeWHO Regional Office for South-East Asia21stedition(2025),22October2025Reportingperiod:06to19Oct2025 Thisepidemiological bulletin aims to providethe situation of key infectiousdiseases intheWHOSouth-East AsiaRegionto inform risk assessmentsand responses. The bulletin usesinformation from publicly availablesources and Key events and updates......................................................................................................................2India: Substandard (contaminated) oral liquid medicines.........................................................................................2Bangladesh: Chikungunya.........................................................................................................................................3Influenza............................................................................................................................................4Situation in theWHO South-East Asia Region..........................................................................................................4COVID-19............................................................................................................................................6Mpox.................................................................................................................................................7Situation in the WHO South-East Asia Region..........................................................................................................7Dengue...............................................................................................................................................9Situation in theWHO South-East Asia Region..........................................................................................................9 Key eventsand updates India: Substandard (contaminated) oral liquid medicines •On 13October 2025, WHO issuedMedical Product AlertN°5/2025regardingsubstandard (contaminated) oralliquid medicines identified inIndia and reported to WHO on 8 October 20251. Alert summary •On 8 October the Central Drugs Standard Control Organization (CDSCO) of India reported to WHO the presenceof Diethylene Glycol (DEG) in at least three oral liquid medicines. This followed information identified by WHOon 30 September 2025 of localized clusters of acute illness and child fatalities in India. CDSCO informed WHO •The contaminated oral liquid medicines have been identified to be specific batches of COLDRIF, Respifresh TRand ReLife, manufactured by Sresan Pharmaceutical, Rednex Pharmaceuticals, and Shape Pharma. •CDSCO has confirmed that relevant state authorities have ordered an immediate halt to production atimplicated manufacturing sites and have suspended product authorizations. In addition, a recall of the •The CDSCO has informed WHO that none of the contaminated medicines have been exported from India and •Nevertheless,WHO encourages National Regulatory Authorities(NRAs)to consider targeted marketsurveillance, with particular attention to informal and unregulated supply chains where products may circulateundetected. NRAs are also advised to carefully evaluate the risks associated with any oral liquid medicines •WHO continues to collaborate closely with Indian health authorities to monitor the situation, identify the source Risks •These contaminated products pose significant risks to patients and can cause severe and potentially life-threatening illness. Diethylene glycol is toxic to humans when consumed and can prove fatal. The contaminatedoral liquid medicines referenced in thisalert are unsafe and their use, especially in children, may result in serious •To protect patients, it is essential to detect and remove these contaminated products from circulation. Advice to health-care professionals, regulatory authorities and the public •Health-care professionals should report the detection of thesesubstandard products and any incident ofadverseeffects,or lack of expected effects to their National Regulatory Authorities or NationalPharmacovigilance Centre. WHO advises increased surveillance and diligence within the supply chains of •National regulatory authorities/health authorities, and law enforcement authorities are advised to immediately •If you are in possession of any of these products, WHO recommends that you do not use them. If you, orsomeone you know, has, or may have, used these products, or suffered an adverse event or unexpected side-effect after use, seek immediate medical advicefrom a health-care professional or contact a poisons control •Annex: Products subject of WHO Medical Product Alert N°5/2025 Bangladesh: Chikungunya Situation as of21 October 2025 •Between 1 January and 10 October 2025, a total of 879 suspectedchikungunya cases in Dhaka were reportedby the Institute of Epidemiology and Disease Control and Research (IEDCR), of which 483 were laboratory •Cas